[S-25] New drug development and the change of treatment strategy in MG

[S-25-5] 重症筋無力症の新規治療：Fc融合タンパクAChR-Fc

鵜沢 顕之 (千葉大学大学院医学研究院 脳神経内科学)

We are now experiencing the drastic changes in treatment strategy against MG. The Japanese clinical guidelines recommended lower dose of chronic steroids and early fast-acting treatment strategy. Recently, clinical trial of eculizumab was performed and the drug has been approved. Even after the proposal for these new strategies, nearly half of the MG patients do not achieve minimal manifestations status with prednisolone ≤5mg/day (a treatment target in Japan). Substantial number of patients are still administered insufficiently reduced oral steroids which hamper patients’ quality of life. Therefore, treatment status of MG is still far from our satisfaction. Fortunately, several new drugs are under development presently. In this symposium, we will discuss over the new drug development and adaptation status in real world clinical setting in United States, Europe and Asia.

Department of Neurology, Graduate School of Medicine, Chiba University
Assistant Professor

EDUCATION
1997-2003 M.D., Ryukyu University School of Medicine
2008-2012 Ph.D. in Neurology, Graduate School of Medicine, Chiba University

CAREER
2003-2005 Department of Neurology, Chiba University Hospital
2005-2006 Department of Neurology, Chiba Municipal Aoba Hospital
2006-2007 Department of Neurology, Chiba Rosai Hospital
2007-2008 Department of Neurology, Matsudo Municipal Hospital
2008-2012 Department of Neurology, Chiba University Hospital
2012- Department of Neurology, Graduate School of Medicine, Chiba University

SPECIALITY
Neuroimmunology (myasthenia gravis; multiple sclerosis; neuromyelitis optica)

AWARDS
2018 Best Oral Presentation Award, Annual Meeting of the Japanese Society of Neurology
2012 Asian Oceanian Congress of Neurology, Young Investigator Encouragement